Vanguard Fiduciary Trust
SABS icon

Vanguard Fiduciary Trust’s SAB Biotherapeutics SABS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
373,980
+176,361
+89% +$656K ﹤0.01% 2845
2026
Q1 		$757K Buy
+197,619
New +$788K ﹤0.01% 3042

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust's SABS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its SAB Biotherapeutics (SABS) stake by 89% in Q2 2026, buying an estimated $656K and bringing the position to 373,980 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

Vanguard Fiduciary Trust first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Vanguard Fiduciary Trust held 373,980 shares of SAB Biotherapeutics worth $1.46M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 176,361 SAB Biotherapeutics shares in Q2 2026, an estimated $656K.
  • SAB Biotherapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2845 holding.
  • Vanguard Fiduciary Trust first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.